This company listing is no longer active
Alliance Pharma (APH) Stock Overview
A holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for APH from our risk checks.
APH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alliance Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.65 |
| 52 Week High | UK£0.66 |
| 52 Week Low | UK£0.32 |
| Beta | 0.58 |
| 1 Month Change | 0.78% |
| 3 Month Change | 5.20% |
| 1 Year Change | 88.63% |
| 3 Year Change | -43.15% |
| 5 Year Change | -11.97% |
| Change since IPO | 223.50% |
Recent News & Updates
Recent updates
Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues
Sep 10
Is Alliance Pharma (LON:APH) A Risky Investment?
Jun 21Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet
Feb 23Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)
Nov 21We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt
May 26Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models
Mar 24We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt
Sep 30An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued
May 28Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet
Mar 30Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?
Dec 24Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?
Nov 19
Shareholder Returns
| APH | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.2% | -1.2% | -0.2% |
| 1Y | 88.6% | 19.3% | 20.4% |
Return vs Industry: APH exceeded the UK Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: APH exceeded the UK Market which returned 0.1% over the past year.
Price Volatility
| APH volatility | |
|---|---|
| APH Average Weekly Movement | 1.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: APH has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: APH's weekly volatility has decreased from 7% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 290 | Nick Sedgwick | www.alliancepharmaceuticals.com |
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc Fundamentals Summary
| APH fundamental statistics | |
|---|---|
| Market cap | UK£350.27m |
| Earnings (TTM) | -UK£10.73m |
| Revenue (TTM) | UK£178.84m |
Is APH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APH income statement (TTM) | |
|---|---|
| Revenue | UK£178.84m |
| Cost of Revenue | UK£69.55m |
| Gross Profit | UK£109.29m |
| Other Expenses | UK£120.02m |
| Earnings | -UK£10.73m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 61.11% |
| Net Profit Margin | -6.00% |
| Debt/Equity Ratio | 44.5% |
How did APH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 14:38 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alliance Pharma plc is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Julie Simmonds | Canaccord Genuity |
| Mark Brewer | Cavendish |